Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023

Influenza and Other Respiratory Viruses(2024)10.1111/irv.70027Source: DataRank Database

Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023 is a research paper published in Influenza and Other Respiratory Viruses (2024). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.06)OA: goldTopics (53)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (53)

Diya Surie ORCID,Yuwei Zhu ORCID,Adam S. Lauring ORCID,Manjusha Gaglani ORCID,Tresa McNeal ORCID

Live enrichment

PubMed:39496339 OpenAlex:https://openalex.org/W4404027208

Centers for Disease Control and Prevention

Grant: 75D30122C14944

NIGMS NIH HHS

Grant: R35 GM151147

FWCI

3.06

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/irv.70027

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/irv.70027

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.70027

journalhttps://doi.org/10.1111/irv.70027

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39496339

Fields of Study

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research StudiesHumansCOVID-19HospitalizationCOVID-19 VaccinesMaleFemaleUnited StatesMiddle AgedAgedAdultVaccine EfficacySARS-CoV-2Case-Control StudiesYoung AdultVaccinationAged, 80 and overAdolescent

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesVaccine EfficacyAdolescentAdultAgedAged, 80 and overFemaleHospitalizationHumansMaleMiddle AgedUnited StatesVaccinationCase-Control StudiesYoung Adult

Keywords

MedicineCoronavirus disease 2019 (COVID-19)Bivalent (engine)VaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Logistic regression2019-20 coronavirus outbreakPediatricsInternal medicineVirologyOutbreakCOVID‐19COVID‐19 vaccinesUnited Statesadulthospitalization

Sustainable Development Goals

SDG 0: Good health and well-being